
Our business strategy is based on the following business drivers:
Leveraging presence of our marketed vaccines in public and private markets
We have established products in hepatitis B, pediatric, respiratory and travel vaccines. We intend to enhance our position in these markets by highlighting the unique features of these products and by providing outstanding customer service in terms of delivery, reliability and quality, and by leveraging our worldwide presence in both public and private markets.
Product pipeline with competitive advantage
We believe that each of our selected products either targets unmet medical needs, improves current medications, or is perceived as a marketable product due to predictive study models and/or due to perceived favorable regulatory conditions. We currently have four vaccine programs in clinical trials of which two are in Phase III or registration, and five vaccine programs and one antibody program in various stages of pre-clinical development, which are based on our PER.C6® production technology. In addition, we have various discovery programs to find new vaccine, antibody and therapeutic protein leads.
Ongoing technology licensing program
We have a broad base of excellent technologies with applicability for vaccines, antibodies, other recombinant proteins and gene therapy products. In areas where we are not developing our own products, we offer our technologies to the biopharmaceutical industry for the development and production of diverse biopharmaceutical products.
The ongoing and extensive PER.C6® technology licensing program, and the as yet more limited licensing programs for our other technologies, support and accelerate our in-house product development. Our licensing program provides a source of revenue as well as the potential for future, additional revenue in the form of royalties from products developed by our licensees. We believe that our licensing program results in increased awareness in, and acceptance by, the biopharmaceutical industry and the regulatory authorities of our technology as a production technology for biopharmaceutical products.
|